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A BS T R AC T
BACKGROUND

Some studies have suggested that in people with type 2 diabetes, Roux-en-Y gastric
bypass has therapeutic effects on metabolic function that are independent of
weight loss.
METHODS

We evaluated metabolic regulators of glucose homeostasis before and after
matched (approximately 18%) weight loss induced by gastric bypass (surgery
group) or diet alone (diet group) in 22 patients with obesity and diabetes. The
primary outcome was the change in hepatic insulin sensitivity, assessed by infusion of insulin at low rates (stages 1 and 2 of a 3-stage hyperinsulinemic euglycemic pancreatic clamp). Secondary outcomes were changes in muscle insulin sensitivity, beta-cell function, and 24-hour plasma glucose and insulin profiles.
RESULTS

Weight loss was associated with increases in mean suppression of glucose production from baseline, by 7.04 μmol per kilogram of fat-free mass per minute (95%
confidence interval [CI], 4.74 to 9.33) in the diet group and by 7.02 μmol per kilogram of fat-free mass per minute (95% CI, 3.21 to 10.84) in the surgery group
during clamp stage 1, and by 5.39 (95% CI, 2.44 to 8.34) and 5.37 (95% CI, 2.41
to 8.33) μmol per kilogram of fat-free mass per minute in the two groups, respectively, during clamp stage 2; there were no significant differences between the
groups. Weight loss was associated with increased insulin-stimulated glucose
disposal, from 30.5±15.9 to 61.6±13.0 μmol per kilogram of fat-free mass per
minute in the diet group and from 29.4±12.6 to 54.5±10.4 μmol per kilogram of
fat-free mass per minute in the surgery group; there was no significant difference
between the groups. Weight loss increased beta-cell function (insulin secretion
relative to insulin sensitivity) by 1.83 units (95% CI, 1.22 to 2.44) in the diet group
and by 1.11 units (95% CI, 0.08 to 2.15) in the surgery group, with no significant
difference between the groups, and it decreased the areas under the curve for 24hour plasma glucose and insulin levels in both groups, with no significant difference between the groups. No major complications occurred in either group.
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CONCLUSIONS

In this study involving patients with obesity and type 2 diabetes, the metabolic
benefits of gastric bypass surgery and diet were similar and were apparently related to weight loss itself, with no evident clinically important effects independent
of weight loss. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT02207777.)
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andomized clinical trials have
shown that bariatric surgery is more effective than medical therapy for treatment
of type 2 diabetes.1-6 Moreover, several studies
suggest that surgical procedures that involve
bypass of the upper gastrointestinal tract, such
as Roux-en-Y gastric bypass, have unique therapeutic effects on glycemic control, as evidenced
by the higher incidence of diabetes remission
after gastric bypass than after procedures that
maintain intestinal continuity.7-9 However, the
results from such studies are confounded by differences in weight loss among patients who undergo the procedures. The effects of gastric bypass, independent of weight loss, on the major
factors involved in the pathogenesis of type 2
diabetes, namely multiorgan insulin resistance,
alterations in the metabolic response to meal
ingestion, and inadequate beta-cell function, are
unclear because of conflicting results among
studies10,11 and because data on several of these
factors are limited.
The present study was designed to determine
whether gastric bypass confers therapeutic metabolic effects independent of weight loss in people with obesity and type 2 diabetes. We compared the effects of marked weight loss induced
by Roux-en-Y gastric bypass with the effects of
the same weight loss induced by a low-calorie
diet alone on hepatic insulin sensitivity (primary
outcome) and muscle and adipose tissue insulin
sensitivity; beta-cell function; the metabolic response to mixed-meal ingestion; 24-hour plasma
glucose, free fatty acid, and insulin profiles; and
body composition. We also evaluated several factors purported to be associated with benefits of
gastric bypass independent of weight loss: alterations in plasma branched-chain amino acids,
plasma bile acids, and the gut microbiome.12-15

Me thods
Study Design and Oversight

This matched prospective cohort study was conducted from November 2014 through October
2018. A comprehensive assessment of metabolic
function was conducted before and after marked
(16 to 24%) weight loss induced by Roux-en-Y
gastric bypass (surgery group) or low-calorie diet
therapy (diet group) in persons with obesity and
type 2 diabetes. Participants provided written
informed consent before participating in this
study, which was approved by the Washington
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University institutional review board. The last
author had full access to all data and was responsible for the design and conduct of the
study, the collection, analysis and interpretation
of the data, and the preparation of the manuscript. The authors collaborated in preparing
the manuscript, made the decision to submit the
manuscript for publication, and vouch for the
accuracy and completeness of the data and for
the fidelity of the study to the protocol (available
with the full text of this article at NEJM.org).
Weight-Loss Interventions

Participants in the diet group received weekly
education sessions on dietary practices and guidance on dietary behavior. All meals were provided throughout the study as liquid shakes and
prepackaged entrees. The gastric bypass procedure involved creation of a 15-to-20-ml gastric
pouch, a 75-to-150-cm Roux limb, and a 30-to50-cm biliopancreatic limb.16 A study dietitian
consulted with surgery patients weekly to monitor body weight and adjust dietary intake to meet
weight-loss goals. After participants achieved
the targeted weight loss, their energy intake was
adjusted to maintain a constant body weight for
3 weeks before repeat testing was performed. The
mean (±SD) coefficient of variation in weekly
body weights during this period was 1.2±0.5%
(range, 0.3 to 1.8) in the diet group and
1.2±0.4% (range, 0.7 to 1.8) in the surgery group.
Study Outcomes and Procedures

The primary outcome was the change in hepatic
insulin sensitivity. Secondary outcomes were
changes in insulin sensitivity in muscle and adipose tissue; beta-cell function; metabolic response to mixed-meal ingestion; 24-hour glucose,
free fatty acid and insulin profiles; and body
composition.
Glucagon-like peptide-1 receptor agonists were
discontinued 2 weeks before each metabolic
study, oral diabetes medications were discontinued 3 days before, and insulin was discontinued
1 day before to reduce their effects on metabolic
outcomes. Diabetes medications were adjusted
on the basis of twice-daily blood glucose measurements. A diabetes medication score was
calculated on the basis of the number and dose
of medications (scores ranged from 0 to 3.57,
with a higher score indicating a greater number
of medications, a higher dosage of medications,
or both; details are provided in the Calculations
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section in the Supplementary Appendix, available at NEJM.org).17
Participants were admitted to the research
unit at Washington University School of Medicine in St. Louis for analysis of body composition18 and a 9-hour, three-stage hyperinsulinemic euglycemic pancreatic clamp procedure to
assess hepatic, muscle, and adipose tissue insulin sensitivity. This procedure involved infusion
of stable isotope tracers, octreotide to block insulin secretion, and insulin at increasing rates
every 3 hours (from 15 to 25 to 50 mU per square
meter of body-surface area per minute). Participants were readmitted to the research unit 1 to
2 weeks later for a 7-hour mixed-meal test to
assess postprandial glucose and insulin kinetics16
and 24-hour plasma glucose, free fatty acid, and
insulin profiles. Beta-cell function was assessed
as the product of beta-cell glucose sensitivity
(the ratio of postprandial insulin secretion rate
to postprandial plasma glucose) during the
mixed-meal test and whole-body insulin sensitivity assessed during the clamp procedure.16,19
Fecal samples were obtained during an inpatient
visit to the research unit. (Details of all procedures and analyses are provided in the Supplementary Appendix.)

R e sult s
Participants

A total of 33 people with obesity and type 2 diabetes participated in this study: 18 in the diet
group and 15 in the surgery group (inclusion
and exclusion criteria are described in the Supplementary Appendix). Seven participants in the
diet group and 4 in the surgery group withdrew
or were withdrawn from the study because they
did not achieve the target weight loss (Fig. S1 in
the Supplementary Appendix). Accordingly, data
from 11 participants (4 men and 7 women) in the
diet group (mean age, 54±9 years; mean time since
diagnosis of diabetes, 9.1±5.6 years) and 11 participants (3 men and 8 women) in the surgery
group (mean age, 49±12 years; mean time since
diagnosis of diabetes, 9.6±9.6 years) were analyzed before and after weight loss. The mean
weight loss was 17.8±1.2% (range, 16.1 to 20.4) in
the diet group and 18.7±2.5% (range, 16.0 to 24.4)
in the surgery group. During the study, two adverse
events occurred in the surgery group (one postoperative transfusion of 2 units of blood and one
emergency department visit for food impaction),
and no adverse events occurred in the diet group.
Body Composition, Basal Metabolic Variables,
and Glycemic Control

Statistical Analysis

An analysis of covariance, with the postintervention value as the dependent variable and the
baseline value and group assignment as predictor variables, was used to assess the effects on
outcomes of weight loss induced by diet as compared with surgery. Assumptions for all models
were confirmed by regression residuals. (Additional details are provided in the Statistical Analyses section in the Supplementary Appendix.)
We assumed that weight loss would increase
insulin-mediated suppression of glucose production from 43±13% at baseline to 62±13% after
weight loss in the diet group and to 75±13%
after weight loss in the surgery group.20-23 We
calculated that 18 participants in each treatment group would be needed to give the study
83% power to detect this difference of 13 percentage points in hepatic insulin sensitivity between groups at a two-tailed alpha value of 0.05.
On the basis of our previous experience, we
anticipated that 25% of the participants would
drop out because they did not achieve adequate
weight loss or were unwilling to return for
testing.
n engl j med 383;8

Weight loss was associated with changes in body
composition, plasma glucose and hormone concentrations, and glycated hemoglobin levels, with
no significant differences between the groups
(Table 1). The diabetes medication score decreased from 0.93±0.55 to 0.23±0.29 (mean difference, −0.70; 95% confidence interval [CI],
−1.06 to −0.33) in the diet group and from
1.64±1.15 to 0.60±0.78 (mean difference, −1.04;
95% CI, −1.70 to −0.40) in the surgery group,
with no significant difference between the groups.
Four participants in the diet group and two in the
surgery group reached glycated hemoglobin levels
lower than 6.0% without diabetes medications.
Postprandial and 24-Hour Glucose, Fatty
Acid, and Insulin Kinetics

Areas under the curve for plasma glucose and
insulin after ingestion of the identical breakfast
mixed meal were lower after weight loss than
before in both groups; the decrease in glucose,
but not insulin, was greater in the diet group than
in the surgery group (Table 2). The postprandial
peak in plasma glucose after weight loss was
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20.3±6.7
8.0±2.1
1.88±1.12
107±77

Insulin (μU/ml)

Glycated hemoglobin (%)

High-molecular-weight adiponectin
(μg/ml)

Leptin (ng/liter)

47±39

2.65±1.51
−61 (−91 to −31)

0.77 (0.19 to 1.35)

−2.4 (−3.7 to −1.1)

−8.3 (−13.1 to −3.5)

−51 (−78 to −23)

−4.0 (−8.8 to 0.84)

−9.4 (−15.0 to −3.7)

−821 (−1066 to −576)

−4.8 (−6.3 to −3.2)

−6.0 (−7.1 to −5.0)

−16.0 (−18.3 to −13.7)

−7.7 (−8.6 to −6.7)

−21.9 (−25.0 to −18.8)

105±64

1.31±0.98

7.2±1.3

27.0±11.3

153±29

21.7±4.2

16.9±10.9

2463±996

62.0±11.7

48.9±4.6

59.1±9.0

43.2±3.8

122.3±18.2

37±21

2.31±1.75

6.0±0.7

9.3±5.0

106±16

15.1±6.3

5.8±4.8

1749±675

55.9±11.4

44.0±5.9

43.5±7.5

35.1±2.9

99.3±14.3

−68 (−100 to −36)

1.0 (0.35 to 1.64)

−1.2 (−2.2 to −0.18)

−17.7 (−25.9 to −9.6)

−47 (−62 to −32)

−6.5 (−9.5 to −3.6)

−11.1 (−18.8 to −3.4)

−714 (−1082 to −346)

−6.1 (−7.3 to −4.8)

−5.0 (−6.2 to −3.7)

−15.6 (−18.2 to −13.0)

−8.1 (−9.1 to −7.1)

−23.0 (−26.5 to −19.4)

Difference (95% CI)

−8.5 (−23.1 to 6.1)

0.07 (−0.08 to 0.22)

0.52 (−0.11 to 1.14)

−3.5 (−7.5 to 0.5)

0.7 (−9.9 to 11.4)

−0.9 (−5.6 to 3.9)

1.4 (−2.0 to 4.9)

157 (−128 to 442)

−1.32 (−3.06 to 0.43)

1.00 (−0.47 to 2.47)

0.58 (−1.98 to 3.14)

−0.39 (−1.18 to 0.39)

−1.1 (−3.4 to 1.2)

Difference between
Groups (95% CI)

of

5.6±0.7

11.9±2.9

106±10

15.0±4.0

3.8±1.3

1485±630

57.5±12.8

42.4±8.2

42.2±10.7

35.2±5.6

100.3±17.3

Before Weight After Weight
Loss
Loss

Surgery Group

n e w e ng l a n d j o u r na l

*	Plus–minus values are means ±SD. To convert the values for glucose to millimoles per liter, multiply by 0.05551. To convert the values for insulin to picomoles per liter, multiply by
6.0. To convert the values for free fatty acid to grams per liter, multiply by 0.01. The within-group difference is the mean with 95% confidence interval (CI) for the difference between the
value before weight loss and the value after weight loss within each group. The difference between groups is the difference (and 95% CI) between the group means of the values after
weight loss, adjusted for the values before weight loss by analysis of covariance.
†	The body-mass index is the weight in kilograms divided by the square of the height in meters.

156±45

Glucose (mg/dl)

18.9±7.3

62.3±13.9

Fat-free mass (kg)

Free fatty acids (mg/dl)

48.4±7.6

Body fat (%)

13.2±7.6

58.2±12.9

Intrahepatic triglyceride content (%)

42.9±6.9

Fat mass (kg)

122.2±21.7

Difference (95% CI)

Diet Group
Before Weight After Weight
Loss
Loss

Body-mass index†

Body weight (kg)

Variable

Table 1. Body Composition and Basal Metabolic Variables before and after Weight Loss.*
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2.14±0.22

24-Hr insulin secretion rate AUC — pmol/
min × 103

24-Hr insulin clearance rate — liters/min

Difference (95% CI)

0.77 (0.34 to 1.20)

−161 (−313 to −8)

−39 (−70 to −8)

−5.7 (−9.2 to −2.2)

–142 (−219 to −64)

−910 (−1440 to −383)

130 (−109 to 338)

−770 (−1460 to −98)

−5.6 (−11.8 to 0.66)

−20.8 (−31.8 to −9.84)

Before

1.90±0.13

929±231

85±32

22.0±6.1

322±99

2490±979

3560±956

6050±1010

17.0±8.3

50.5±14.3

2.90±0.25

742±281

47±27

17.1±5.4

204±61

1750±406

3790±749

5530±1030

12.4±6.6

40.4±12.0

After

1.0 (0.46 to 1.54)

−187 (−345 to −29)

−38 (−63 to −12)

−4.9 (−6.9 to −2.9)

−118 (−172 to −64)

−740 (−1481 to −9)

230 (−572 to 1020)

−520 (−1250 to 202)

−4.6 (−9.3 to 0.06)

−10.1 (−17.7 to −2.6)

Difference (95% CI)

Surgery Group

0.11 (−0.47 to 0.70)

−31 (−193 to 130)

1 (−17 to 20)

2.7 (−0.2 to 5.6)

32 (−1 to 66)

159 (−184 to 501)

−19 (−599 to 561)

138 (−630 to 905)

−3.5 (−7.5 to 0.5)

8.6 (1.1 to 16.0)

Difference between
Groups (95% CI)

*	Plus–minus values are means ±SD. To convert the values for C-peptide to nanograms per milliliter, multiply by 0.331. The within-group differences are the mean and 95% CI for the difference between the value before weight loss and the value after weight loss within each group. The difference between groups is the difference (and 95% CI) between the group means
of the values after weight loss, adjusted for the values before weight loss by analysis of covariance. The area under the curve (AUC) was calculated with data from the time ingestion of
the breakfast meal began to either 4 hours or 24 hours later. Glucose rate of appearance (RA) 4-hr AUC is the AUC for the total glucose RA (i.e., the sum of ingested glucose RA and
endogenous glucose RA) into the systemic circulation from the time meal ingestion began until 4 hours after the meal. FFM denotes fat-free mass.

2.91±0.18

46±14
779±214

84±54
940±377

24-Hr insulin AUC — μU/ml × min × 103

12.9±2.1

18.6±5.9

24-Hr free fatty acid AUC — mg/
dl × min × 103

1590±313
169±25

2500±751

Endogenous glucose RA 4-hr AUC — μmol/
kg FFM/min × min

3910±728

311±132

3780±834

Ingested glucose RA 4-hr AUC — μmol/
kg FFM/min × min

5500±867

10.9±3.7

33.1±6.7

After

Diet Group

24-Hr glucose AUC — mg/dl × min × 103

6270±1204

16.5±8.8

53.9±18.9

Total glucose RA 4-hr AUC — μmol/kg FFM/
min × min

4-Hr meal insulin AUC — μU/ml × min × 10

3

4-Hr meal glucose AUC — mg/dl × min × 103

Variable

Table 2. Metabolic Response to Mixed-Meal Ingestion and 24-hour Plasma Glucose, Free Fatty Acid, and Insulin Profile before and after Weight Loss.*
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After weight loss

A Plasma Glucose

Glucose (mg/dl)

Diet

Surgery

300

300

200

200

100

100

0

0

60

120

180

0

240

0

60

120

180

240

180

240

180

240

180

240

Minutes

B Total Glucose Rate of Appearance

Rate of Appearance
(µmol/kg FFM/min)

Diet

Surgery

120

120

100

100

80

80

60

60

40

40

20

20

0

0

60

120

180

0

240

0

60

120

Minutes

C Ingested Glucose Rate of Appearance

Rate of Appearance
(µmol/kg FFM/min)

Diet

Surgery

100

100

80

80

60

60

40

40

20

20

0

0

−20

−20

0

60

120

180

240

0

60

120

Minutes

D Endogenous Glucose Production Rate

Production Rate
(µmol/kg FFM/min)

Diet

Surgery

25

25

20

20

15

15

10

10

5

5

0

0

60

120

180

0

240

0

60

120

Minutes
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Figure 1 (facing page). Effects of Weight Loss Induced
by Diet and Gastric Bypass on Postprandial Glucose
Kinetics.
Shown are mean levels of plasma glucose (Panel A), total
glucose rate of appearance in the systemic circulation
(Panel B), ingested glucose rate of appearance (Panel C),
and endogenous glucose production rate (Panel D) after
ingestion of an identical mixed meal (consumed from
time 0 to 30 minutes) before (white circles) and after
(black circles) weight loss induced by low-calorie diet
therapy (Diet, 11 participants) or gastric bypass (Surgery,
9 participants). Decreases in postprandial areas under
the curve after weight loss for plasma glucose concentration, total glucose rate of appearance, and endogenous glucose production rate were not significantly different between the two groups. To convert the values for
glucose to millimoles per liter, multiply by 0.05551. I bars
indicate standard errors. FFM denotes fat-free mass.

greater in the surgery group than in the diet
group, a difference caused by a marked increase
in the rate of delivery of ingested glucose into
the circulation (Fig. 1). The effect of weight loss
on meal-induced suppression of endogenous glucose production did not differ significantly between the two groups (Table 2 and Fig. 1).
Although the composition of the meals provided during the 24-hour study was the same
before and after weight loss, the energy content
was individualized on the basis of each participant’s measured resting energy expenditure. Therefore, energy consumption was lower after weight
loss (2091±136 kcal per day) than before weight
loss (2520±183 kcal per day). Weight loss decreased the 24-hour areas under the curve for
glucose, free fatty acids and insulin, and insulin
secretion rate, with no significant differences
between the diet and surgery groups (Table 2).
The shape of the plasma concentration curves
differed between the groups, manifested by higher peaks in both substrate and hormone concentrations immediately after meal ingestion in the
surgery group than in the diet group (Fig. 2).
Multiorgan Insulin Sensitivity and Beta-Cell
Function

Insulin sensitivity in the liver (suppression of
glucose production during stages 1 and 2 of the
clamp procedure), skeletal muscle (stimulation
of glucose disposal during stage 3 of the clamp
procedure), and adipose tissue (suppression of
lipolysis during stages 1 and 2 of the clamp
procedure) increased after weight loss in both

n engl j med 383;8

the diet and surgery groups, with no significant
differences between the groups (Table 3). Weight
loss increased beta-cell function in both groups,
which appeared to be caused by an increase in
beta-cell glucose sensitivity and whole-body insulin sensitivity (Table 3).
Other Weight-Loss–Independent Therapeutic
Effects of Gastric Bypass

Several factors are purported to result in therapeutic effects of gastric bypass that are independent of weight loss. The decreases in 24-hour
plasma branched-chain amino acid and C3 and
C5 acylcarnitine concentrations after weight loss
were greater in the surgery group than in the
diet group. Plasma bile acids after weight loss
were decreased from baseline in the diet group,
but were increased from baseline in the surgery
group. Weight loss caused changes in the composition of the gut microbiome in both treatment
groups, but the changes were greater in the surgery group than in the diet group. (For additional details, see Fig. S2).

Discussion
We evaluated whether Roux-en-Y gastric bypass
has therapeutic effects independent of weight
loss on the major physiologic factors that regulate glycemic control in people with obesity and
type 2 diabetes. To this end, we assessed the
metabolic response to mixed-meal ingestion, 24hour glucose, free fatty acid and insulin profiles,
multiorgan insulin sensitivity, and beta-cell function before and after matched (approximately
18%) weight loss induced by gastric bypass surgery or diet therapy alone. A three-stage hyperinsulinemic euglycemic pancreatic clamp was
used to control both portal and systemic plasma
insulin concentrations to provide a reliable assessment of hepatic, muscle, and adipose tissue
insulin sensitivity across a physiologic range of
plasma insulin concentrations. Our data show
that after marked weight loss induced by either
diet therapy or gastric bypass, there were considerable improvements in body composition (body
fat mass, intraabdominal adipose tissue volume,
and intrahepatic triglyceride content); 24-hour
plasma glucose, free fatty acid, and insulin profiles; beta-cell function; and insulin sensitivity
in the liver, skeletal muscle, and adipose tissue,
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Before weight loss

of
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After weight loss

A Serial Plasma Glucose

Glucose (mg/dl)

Diet

Surgery

300

300

200

200

100

100

0

0

4

8

12

16

20

24

0

0

4

8

12

16

20

24

16

20

24

16

20

24

16

20

24

Hours

B Free Fatty Acid
Free Fatty Acid (mg/dl)

Diet

Surgery

25

25

20

20

15
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18

15

15

12
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9

9

6

6

3
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0

4
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0

4

8
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D Insulin

Insulin (µU/ml)

Diet

Surgery
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100

50

50
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0

4

8
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16

20

24

0

0

4

8

12
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with no significant differences between the the metabolic benefits of gastric bypass surgery
groups in any of these variables. These results are probably the result of weight loss alone.
underscore the potent therapeutic effects of
In contrast to weight loss induced by diet
weight loss on metabolic function and show that alone, weight loss induced by gastric bypass was
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Figure 2 (facing page). Effects of Weight Loss Induced
by Diet and Gastric Bypass on 24-hour Plasma Glucose,
Free Fatty Acid, C-Peptide, and Insulin Concentrations.
Shown are mean levels of concentrations of plasma
glucose (Panel A), free fatty acid (Panel B), C-peptide
(Panel C), and insulin (Panel D) from serial samples
obtained for 24 hours before (white circles) and after
(black circles) weight loss induced by low-calorie diet
therapy (Diet, 11 participants) or gastric bypass (Surgery, 8 participants). Gray bars represent the time of
mixed-meal consumption. Average 24-hour plasma glucose, free fatty acid, and insulin concentrations were
lower after treatment than before treatment in both the
diet and surgery groups, with no significant difference
between the groups. To convert the values for free fatty
acids to grams per liter, multiply by 0.01; to convert the
values for C-peptide to nanograms per milliliter, multiply by 0.331. I bars indicate standard errors.

associated with marked alterations in the pattern of the metabolic response to mixed-meal
ingestion, manifested by a rapid delivery of ingested glucose into the systemic circulation and
a concomitant large early rise and fall in plasma
glucose and insulin concentrations. Despite
these differences, weight loss had the same beneficial effects on overall postprandial glucose
and insulin kinetics in the two groups. In addition, weight loss decreased the integrated 24hour plasma glucose and insulin concentrations
by about 40% from baseline in both the diet and
surgery groups, even though the total dose of
diabetes medications for participants in both
groups decreased by approximately 75%. The
improved 24-hour metabolic profile was presumably caused by improvements in beta-cell
function and multiorgan insulin sensitivity, in
conjunction with a decrease from baseline in
total carbohydrate and energy intake.
Multiorgan insulin resistance is a universal
feature of type 2 diabetes and is involved in the
pathogenesis of cardiometabolic diseases associated with diabetes.24-27 Hepatic glucose production is more sensitive to insulin than is skeletal
muscle glucose uptake.28 Accordingly, the assessment of hepatic insulin sensitivity requires low
doses of insulin to partially suppress glucose
production, whereas higher doses are needed to
adequately stimulate muscle glucose disposal.
The assessment of hepatic insulin sensitivity is
particularly complicated because portal vein insulin is higher than systemic plasma insulin,29
and the feedback suppression of insulin secren engl j med 383;8

tion by circulating insulin is blunted in people
with obesity.30 Therefore, we infused octreotide
during the clamp procedure to block endogenous insulin secretion in order to ensure that
similar portal vein insulin concentrations were
achieved before and after weight loss. Moreover,
we provided a comprehensive assessment of hepatic insulin sensitivity by infusing insulin at
two rates that spanned the physiologic range
needed to partially suppress hepatic glucose
production. Our data showed that weight loss
caused considerable improvement in the ability
of insulin to suppress both glucose production
and lipolysis and to stimulate glucose disposal,
with no significant differences between the diet
and surgery groups.
The ability of beta cells to secrete an adequate
amount of insulin in response to a glucose challenge is critical for normal glucose homeostasis
and is an important predictor of diabetes remission after weight loss induced by gastric bypass.31,32 We assessed beta-cell function as the
product of beta-cell glucose sensitivity after
mixed-meal ingestion and whole-body insulin
sensitivity assessed during the clamp procedure.
The interpretation of insulin secretion in relation to insulin sensitivity is necessary because
the amount of insulin needed for glycemic control depends on the effectiveness of insulin.
Weight loss markedly increased beta-cell function because of an increase in both beta-cell
glucose sensitivity and whole-body insulin sensitivity in both the diet and surgery groups, with
no significant differences between the groups.
Several mechanisms have been purported to
cause metabolic benefits of gastric bypass that
are independent of weight loss, including decreased plasma branched-chain amino acids and
their acylcarnitines,12 increased circulating bile
acids,13 and alterations in the gut microbiome.14,15
We found that patients in the surgery group had
a greater decline in plasma concentrations of
branched-chain amino acids and C3 and C5 acylcarnitines and a greater increase in plasma bile
acids than patients in the diet group — a finding consistent with results from previous studies.12,13 The changes observed in the gut microbiome of persons in the surgery group are also
consistent with the results from most studies15,33-39 and were much greater than the changes
observed in the diet group. These results confirm that gastric bypass causes alterations in spe-
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*	Plus–minus values are means ±SD. The within-group difference is the mean with 95% CI for the difference between the value before weight loss and the value after weight loss within
each group. The difference between groups is the difference (and 95% CI) between the group means of the values after weight loss, adjusted for the values before weight loss by analysis of covariance. RD denotes rate of disposal from the systemic circulation.
†	Beta-cell function was assessed as the product of beta-cell glucose sensitivity (the ratio of postprandial total area under the curve of insulin secretion rate to total area under the curve
of postprandial plasma glucose) and whole-body insulin sensitivity (glucose infusion rate divided by the plasma insulin concentration during stage 3 of the hyperinsulinemic euglycemic
pancreatic clamp procedure).

–0.71 (–1.75 to 0.34)
1.11 (0.08 to 2.15)
2.10±1.24
0.99±0.82
2.76±1.20
Beta-cell function†

0.93±0.94

1.83 (1.22 to 2.44)

–0.04 (–0.39 to 031)
–0.77 (–1.23 to –0.31)
0.64±0.31
1.41±0.75
0.65±0.40
1.14±0.76
Palmitate RA (Stage 2) — μmol/kg
FFM/min

–0.49 (–1.06 to 0.08)

0.33 (–0.26 to 0.91)
–1.07 (–2.11 to –0.03)
1.17±0.74
2.24±1.13
–0.97 (–1.30 to –0.64)
1.78±0.55
Palmitate RA (Stage 1) — μmol/kg
FFM/min

0.81±0.41

–6.5 (–15.7 to 2.7)
25.1 (16.4 to 33.8)
54.5±10.4
29.4±12.6
31.0 (22.5 to 39.6)
30.5±15.9
Glucose RD (Stage 3) — μmol/kg
FFM/min

61.6±13.0

0.02 (–2.00 to 2.04)
–5.37 (–8.33 to –2.41)
3.47±0.77
8.84±4.08
–5.39 (–8.34 to –2.44)
8.84±3.91
Glucose RA (Stage 2) — μmol/kg
FFM/min

3.45±2.74

–7.02 (–10.84 to –3.21)

Difference (95% CI)
After

10.42±4.30
17.44±4.99

Before
Difference (95% CI)

–7.04 (–9.33 to –4.74)
10.03±3.08

After
Before

17.07±2.36

Diet Group

Table 3. Multiorgan Insulin Sensitivity and Beta-cell Function before and after Weight Loss.*
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Difference between
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0.25 (–3.08 to 3.59)
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cific plasma metabolites and the gut microbiome
that are independent of weight loss but showed
that these changes were not associated with
greater improvements in metabolic function.
Our study has several limitations. First, treatment assignment was not randomized, so potential confounding differences between groups
cannot be ruled out. Second, it is possible that
unique benefits of surgery were not detected
because of inadequate statistical power and the
large proportion of dropouts. However, this possibility is unlikely because the method used to
assess our primary outcome can detect small
differences in a small number of participants,
and there was no evidence of even a trend in
differences between groups in any outcome.
Third, we evaluated a variety of secondary outcomes that require confirmation because there
was no adjustment for multiple testing. Fourth,
metabolic outcomes were assessed after a weight
loss of 16 to 24%, so we cannot exclude the possibility of different results with lesser or greater
amounts of weight loss. Fifth, we cannot exclude
the possibility that gastric bypass has unique
effects on other important clinical outcomes not
assessed in this study.
The results from our study underscore the
profound effect that marked weight loss can
have on metabolic function in people with diabetes. The similar findings in participants in the
two groups challenge the current belief that upper gastrointestinal bypass has clinically meaningful effects on key metabolic factors involved
in glucose homeostasis and the pathogenesis of
diabetes that are independent of weight loss.
However, the difficulty in achieving successful
long-term weight loss with lifestyle therapy often
renders gastric bypass surgery far more effective
than diet therapy for most patients with obesity
and type 2 diabetes.
We found nearly identical benefits of matched
weight loss induced by gastric bypass or diet
alone on multiorgan insulin sensitivity, beta-cell
function, 24-hour plasma glucose and insulin
profiles, and body composition.
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